LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS
/PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today provided an update on the clinical advancement and development of its biosimilar insulin aspart and...
Source: prnewswire.com